5 Key Takeaways

• 1

  The CDC's ACIP expanded pneumococcal vaccine recommendations to include all adults aged 50 or older, effective October 23, 2024.

• 2

  The updated guidance aims to improve pneumococcal disease prevention in adults aged 50 to 64, especially in high-risk demographic groups.

• 3

  Adults aged 50 or older can receive PCV21, PCV20, or PCV15, with specific recommendations for additional doses of PPSV23.

• 4

  Invasive pneumococcal disease incidence and mortality rates for adults aged 50-64 were reported at 13.2 and 1.8 per 100,000 in 2022.

• 5

  The guidance maintains risk-based recommendations for adults aged 19 to 49 and emphasizes shared decision-making for certain populations.